IDRI Announces Appointment of H. Stewart Parker as Chief Executive Officer

February 15th, 2011|Press Releases|

Seattle, WA | February 15, 2011 The Infectious Disease Research Institute (IDRI) announces today the appointment of H. Stewart Parker as its new Chief Executive Officer and new member of the IDRI board of directors. Parker is a widely [...]

IDRI Awarded Grant from Bill and Melinda Gates Foundation to Identify Candidates for Novel TB Drugs

January 14th, 2011|Press Releases|

Seattle, WA | January 14, 2011 The Infectious Disease Research Institute (IDRI) today announced it has received a multi-million dollar grant from the Bill and Melinda Gates Foundation for "Chemical genomics for the identification of targets and leads in [...]

IDRI Receives DARPA Grant to Develop a Novel Vaccine to Combat Pandemic Flu

January 7th, 2011|Press Releases|

Seattle, WA | January 7, 2011 The Infectious Disease Research Institute (IDRI) today announced it has received a multi-million dollar grant from the Defense Advanced Research Projects Agency (DARPA), and the Army Research Office (ARO), both parts of United [...]

IDRI Awarded $790,200 Grant from US Government to Develop Pandemic Flu Vaccine With Cantacuzino Institute

December 3rd, 2010|Press Releases|

Seattle, WA | December 3, 2010 The Infectious Disease Research Institute (IDRI) today announced it has received a $790,200 grant from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services. [...]

IDRI Awarded Contract from BARDA to Develop Next Generation Adjuvants for Pandemic Influenza

December 3rd, 2010|Press Releases|

Seattle, WA | December 3, 2010 The Infectious Disease Research Institute (IDRI) has been awarded an $1.8 million contract from the Biomedical Advance Research and Development Authority (BARDA). IDRIʼs work will focus on development of adjuvant formulations with options [...]

IDRI Develops Novel Tuberculosis Vaccine, New Study in Science Reports

October 14th, 2010|Press Releases|

Seattle, WA | October 14, 2010 The Infectious Disease Research Institute (IDRI) announces it has developed a new tuberculosis (TB) vaccine that protects against TB including drug-resistant strains of the disease in animal studies. The results of these studies [...]

IDRI and Merial Enter into Research Collaboration

July 14th, 2010|Press Releases|

Seattle, WA | July 14, 2010 Global animal health company Merial Ltd. and non-profit biotechnology organization the Infectious Disease Research Institute (IDRI) today announce they have agreed to cooperate regarding the research and development of certain vaccines for animals. [...]

The Lilly TB Drug Discovery Initiative Announces New Collaborator

November 29th, 2009|Press Releases|

Seattle, WA | November 29, 2009 On behalf of The Lilly TB Drug Discovery Initiative, the Infectious Disease Research Institute (IDRI) today signed a Memorandum of Understanding (MOU) with Academia Sinica, a research institution based in Taiwan, to collaborate [...]

IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis

August 27th, 2009|Press Releases|

Seattle, WA | August 27, 2009 IDRI (Infectious Disease Research Institute) announced today the start of a clinical trial in Sudan to test its leishmaniasis vaccine candidate for the treatment of post kala-azar dermal leishmaniasis (PKDL), a complication of [...]

IDRI Awarded $314,500 Grant From Murdock Trust to Expand TB Drug Discovery Program

June 25th, 2009|Press Releases|

Seattle, WA | June 25, 2009 The Infectious Disease Research Institute today announced it has received a $314,500 grant from the M.J. Murdock Charitable Trust. This new funding will support IDRI's efforts to better understand the mechanisms of tuberculosis [...]

Load More